The Russian Method: What the Research Says About Ozonated Saline IV Therapy
Ozonated saline drips — widely known as the “Russian method” of IV ozone therapy — are having a moment of renewed scientific scrutiny. A 2025 cellular study on ozone’s anti-inflammatory effects and a 2026 published rebuttal challenging its clinical relevance have reopened debate over how this decades-old Eastern European technique compares to Western ozone protocols.
Table of Contents
- What the Russian Method Is
- How It Differs From Major Autohemotherapy
- What Recent Research Shows
- A Live Scientific Debate
- Why This Matters
- Conclusion
What the Russian Method Is
The Russian method of ozone therapy refers to the intravenous drip infusion of ozonated physiological saline — sodium chloride solution that has been bubbled with medical-grade ozone gas immediately before administration. Rather than requiring blood to be drawn, ozonated, and reinfused, the ozone is dissolved directly into saline and delivered gradually into the bloodstream over roughly 15 to 30 minutes. The technique originated in the former Soviet Union and remains formalized by the Russian Association of Ozone Therapy as a core protocol, distinct from the “West European method” of major autohemotherapy used more widely in Western Europe, the US, and parts of Latin America.
How It Differs From Major Autohemotherapy
Major autohemotherapy involves drawing a patient’s own blood, mixing it with ozone/oxygen gas outside the body, and reinfusing it — a process requiring specialized equipment and closer procedural monitoring. The Russian method instead ozonates the saline carrier itself, delivering ozone “drop by drop, molecule by molecule” as the solution enters circulation. Proponents describe this as simpler to administer, requiring smaller needles suitable for patients with difficult venous access or on blood thinners, and eliminating the contamination risk associated with handling blood outside the body. The Russian protocol also characteristically uses lower ozone concentrations delivered over a longer duration, based on the rationale that repeated low-dose exposure produces a more consistent antioxidant response than a single high-dose exposure, which can diminish in effectiveness with repeated use.
What Recent Research Shows
A study published in Molecules in September 2025 by researchers at Sapienza University of Rome examined how ozonated saline solution affects microglial cells (the immune cells of the central nervous system) and endothelial cells in laboratory conditions. At low concentrations (1 and 5 μg/NmL), ozonated saline enhanced cell proliferation without toxicity and triggered an antioxidant response, upregulating protective genes including Nrf2 and SOD1. It also shifted microglial cells toward an anti-inflammatory profile, reducing inflammatory markers like iNOS and IL-1β while increasing anti-inflammatory markers like Arg-1 and IL-10. At the highest tested concentration (10 μg/NmL), however, viability dropped and cell death increased — a finding that underscores why dosing precision matters clinically.
A Live Scientific Debate
The study didn’t go unchallenged. Other researchers in the field published a formal comment disputing the clinical translatability of using isolated cell-line models (BV2 microglial cells) to draw conclusions about whole-body ozonated saline therapy. The original authors published a detailed rebuttal in May 2026, defending the BV2 model’s scientific standing by pointing to its use in thousands of peer-reviewed studies, including papers in Nature, Science, and The Lancet. This back-and-forth is a useful reminder that ozonated saline’s mechanism is still being actively debated in the peer-reviewed literature, even as clinical use continues to expand.
Why This Matters
For integrative practices offering ozone therapy, the Russian method’s growing use in the US reflects real practical advantages — patient comfort, simpler logistics, and a gentler dosing profile that may suit patients who can’t tolerate autohemotherapy. But the current evidence base remains mostly preclinical (cell and animal models) and small pilot studies, rather than large randomized controlled trials in humans. The dose-dependent findings in the 2025 Molecules study are a useful clinical caution: what works as a low-dose anti-inflammatory stimulus can become cytotoxic at higher concentrations, reinforcing why ozone concentration and duration protocols matter and shouldn’t be improvised.
Conclusion
The Russian method remains a widely used but still scientifically contested approach within ozone therapy. Ongoing mechanistic research, and the active peer-review debate around it, suggest the field is moving toward better-defined dosing standards rather than settled consensus — worth watching as more rigorous clinical trials emerge.
Sources
- Armeli, F. et al., “Ozone Saline Solution Polarizes Microglial Cells Towards an Anti-Inflammatory Phenotype,” Molecules, 2025 — Read here
- Armeli, F. et al., “Reply to Franzini et al. The Translational Medicine Regarding Ozone in Saline Solutions,” Molecules, 2026 — Read here
- MedOzons, “The Russian Technology of Ozone Therapy” — Read here
